Endocrinology
News
Dapagliflozin trial in CKD halted because of high efficacy
An independent data monitoring committee recommended stopping the trial.
Conference Coverage
Larger absolute rivaroxaban benefit in diabetes: COMPASS
Latest News
Keep calm: Under 25s with diabetes aren't being hospitalized for COVID-19
But some are concerned that type 1 diabetes diagnoses are being delayed.
News
FDA advises stopping SGLT2 inhibitor treatment prior to surgery
The changes affect canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, and were made because surgery may put patients taking SGLT2...
Latest News
Treating COVID-19 in patients with diabetes
Most health advisories about COVID-2019 mention diabetes as one of the high-risk categories for the disease.
Conference Coverage
Osteoporotic fracture risk is undermanaged in older adults
Study of Medicare database shows decline in treatment of patients who have an increased risk of fracture.
Conference Coverage
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
Conference Coverage
Bethesda system underpredicts malignancy in pediatric thyroid tumors
CHICAGO – Malignancy was more likely in pediatric patients, especially for indeterminate nodules.
Latest News
Levothyroxine dose for checkpoint inhibitor toxicity may be too high
CHICAGO – Dosing need not be automatically boosted when starting checkpoint inhibitor therapy.
Latest News
Dapagliflozin approved for reducing HF hospitalization in diabetes
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.